Clinical trials: Asthma, Allergic
Allergic Asthma
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.
- Trial name
- NCT00492076
- Testing
- Pangramin Plus D. pteronyssinus 100%
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- ALK-Abelló A/S
Asthma
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
This study has the objective of providing compassionate use access to omalizumab (Xolair) and to evaluate the Safety of Xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to…
- Trial name
- NCT00639691
- Testing
- omalizumab
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Novartis
Cat Allergy
Effectiveness of an Air Purifier on Asthmatic and Cat-allergic Subjects in the ALYATEC Environmental Exposure Chamber
The goal of this clinical trial is to evaluate the efficacy of air purifiers in reducing allergy symptoms in patients with a cat allergy.
- Trial name
- NCT06691568
- Testing
- Air purifier
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Dyson Technology Ltd
Bronchial Asthma
OC000459 Bronchial Allergen Challenge
OC0000459 reduces inflammation in the tissues in response to allergic stimuli in patients with asthma. This clinical trial, in mildly asthmatic patients, studies the effects of OC000459 and placebo on the asthmatic response to…
- Trial name
- NCT01056692
- Testing
- OC000459
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Oxagen Ltd
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Allergic Rhinoconjunctivitis
Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract
As part of the registration plan of our products and after performing a Phase I study the present trial has been designed to compare the efficacy of 5 different doses of subcutaneous immunotherapy in depot presentation.
- Trial name
- NCT01564017
- Testing
- Allergovac depot
- Where
- 12 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Roxall Medicina España S.A
Asthma, Mastocytosis
Mast Cell Activation Test in Allergic Disease
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which…
- Conditions
- Asthma, Mastocytosis, Mast Cell Activation Syndrome, Food Allergy
- Trial name
- NCT03406325
- Where
- Hong Kong
- Volunteers
- 19 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Allergic Rhinitis, Asthma
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
The primary objective of this study is to explore the efficacy of Nasonex (mometasone furoate nasal spray) in comparison with placebo in improving the quality of life of subjects with moderate to severe persistent allergic…
- Trial name
- NCT00599027
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 51 people
- Sponsor
- Organon and Co
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Allergy
A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites
A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.
- Trial name
- NCT00660452
- Testing
- Staloral
- Where
- China
- Volunteers
- 484 people
- Sponsor
- Stallergenes Greer
Allergic Rhinoconjunctivitis
Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis
The purpose of ths study is to evaluate changes in life quality of patients affected by rhinoconjuntivitis with or without asthma after immunotherapy treatment.
- Trial name
- ÍCARA (NCT02488447)
- Where
- 14 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Roxall Medicina España S.A
Asthma, Perennial Allergy
Clinical Effects of Temperature Controlled Laminar Airflow (TLA)
The purpose of this study is to determine whether clean air administered to the breathing zone with Temperature controlled Laminar Airflow (TLA) during night is effective in the treatment of perennial allergic asthma.
- Trial name
- NCT00987064
- Testing
- Temperature controlled Laminar Airflow (Protexo)
- Where
- 2 sites in Sweden
- Volunteers
- 28 people
- Sponsor
- Airsonett AB
Asthma, House Dust Mite Allergy
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
The purpose of this study is to investigate the efficacy and safety of different doses of sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01930461
- Testing
- SLIT tablets of HDM allergen extracts, 3 different doses (A), SLIT tablets of HDM allergen extracts, 3 different doses (B), SLIT tablets of HDM allergen extracts, 3 different doses (C)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 386 people
- Sponsor
- Stallergenes Greer
Asthma
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
To evaluate the effect of MEDI-528 in adults with atopic asthma.
- Trial name
- NCT00483041
- Testing
- MEDI528 9 mg/kg
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04898283
- Testing
- 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergic Asthma
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
This study will evaluate the efficacy of QGE031 compared to omalizumab in patients with allergic asthma. Each treatment's effect in changing the concentration of inhaled allergen that is required to elicit a 15% fall in the…
- Trial name
- NCT01703312
- Testing
- QGE031, omalizumab
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA